Small intestine cancer

Summary

Small intestine cancer (MONDO:0000956) is a cancer (an umbrella term covering 6 Mondo subtypes) and 94 clinical trials. Top therapeutic interventions include dextromethorphan, imatinib, and ondansetron. A subtype of small intestine neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 6 Mondo subtypes
• Clinical trials: 94

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	small intestine cancer
Mondo ID	MONDO:0000956
DOID	DOID:10154
ICD-10-CM	C17
ICD-11	906379260
NCIT	C7523
UMLS	C0153425
MedGen	56300
GARD	0009385
Anatomy (UBERON)	UBERON:0002108
Is cancer (heuristic)	yes

Also known as: cancer of small intestine · malignant neoplasm of small bowel · malignant neoplasm of small intestine · malignant neoplasm of the small bowel · malignant neoplasm of the small intestine · malignant neoplasms of the small intestine · malignant small bowel neoplasm · malignant small bowel tumor · malignant small bowel tumour · malignant small intestinal neoplasm · malignant small intestine neoplasm · malignant small intestine tumor · malignant small intestine tumour · malignant tumor of small bowel · malignant tumor of small intestine · malignant tumor of the small bowel · malignant tumor of the small intestine · malignant tumour of small bowel · malignant tumour of small intestine · malignant tumour of the small bowel (+4 more)

Disease family

This is a subtype of small intestine neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › intestinal neoplasm › small intestine neoplasm › small intestine cancer

Related subtypes (8): jejunal neoplasm, small intestinal intraepithelial neoplasia, ileal neoplasm, mesenchymal tumor of small intestine, small intestine neuroendocrine neoplasm, adenoma of small intestine, tumor of duodenum, benign neoplasm of small intestine

Subtypes (6): duodenum cancer, ileum cancer, small intestine lymphoma, small intestinal sarcoma, small intestine carcinoma, jejunal cancer

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 94.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	40
Not specified	23
PHASE2	21
PHASE3	5
PHASE1/PHASE2	4
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00003600	PHASE3	COMPLETED	Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
NCT00003687	PHASE3	COMPLETED	Treatment for Chronic Pain in Patients With Advanced Cancer
NCT00005590	PHASE3	COMPLETED	Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma
NCT00006348	PHASE3	COMPLETED	Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
NCT00026468	PHASE2/PHASE3	WITHDRAWN	Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis
NCT00445497	PHASE3	UNKNOWN	Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia
NCT00003522	PHASE2	TERMINATED	Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine
NCT00003939	PHASE2	COMPLETED	Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma
NCT00004066	PHASE2	COMPLETED	Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
NCT00004895	PHASE2	COMPLETED	Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
NCT00004910	PHASE1/PHASE2	COMPLETED	Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction
NCT00004911	PHASE1/PHASE2	COMPLETED	Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction
NCT00005049	PHASE2	COMPLETED	Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer
NCT00005804	PHASE2	COMPLETED	Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
NCT00005874	PHASE2	COMPLETED	Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas
NCT00006039	PHASE2	COMPLETED	Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin’s Lymphoma
NCT00006357	PHASE1/PHASE2	COMPLETED	STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma
NCT00006379	PHASE2	COMPLETED	Non-Ablative Allo HSCT For Hematologic Malignancies or SAA
NCT00012246	PHASE2	TERMINATED	Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract
NCT00019474	PHASE2	COMPLETED	Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
NCT00025441	PHASE2	COMPLETED	Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors
NCT00079261	PHASE2	COMPLETED	Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin’s Lymphoma
NCT00410462	PHASE2	UNKNOWN	Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma
NCT00416351	PHASE1/PHASE2	COMPLETED	Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin’s Lymphoma That Has Relapsed or Not Responded to Previous Treatment
NCT00433550	PHASE2	COMPLETED	Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
NCT00445965	PHASE2	COMPLETED	Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
NCT00474994	PHASE2	COMPLETED	Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
NCT00589563	PHASE2	COMPLETED	Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
NCT00621036	PHASE2	WITHDRAWN	Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
NCT00669812	PHASE2	UNKNOWN	High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma
NCT00903396	PHASE2	TERMINATED	Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
NCT07060014	PHASE1	NOT_YET_RECRUITING	NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers
NCT00002759	PHASE1	COMPLETED	Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
NCT00003368	PHASE1	COMPLETED	Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis
NCT00003427	PHASE1	COMPLETED	Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
NCT00003993	PHASE1	COMPLETED	Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma
NCT00004002	PHASE1	COMPLETED	PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT00004074	PHASE1	COMPLETED	Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
NCT00004189	PHASE1	COMPLETED	Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer
NCT00004258	PHASE1	COMPLETED	EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DEXTROMETHORPHAN	4	3
IMATINIB	4	3
ONDANSETRON	4	3
EPIRUBICIN HYDROCHLORIDE	4	2
ERLOTINIB HYDROCHLORIDE	4	2
IXABEPILONE	4	2
LEVOFLOXACIN ANHYDROUS	4	2
PHENYLBUTANOIC ACID	4	2
TACROLIMUS ANHYDROUS	4	2
CIPROFLOXACIN	4	1
CLADRIBINE	4	1
CLOFARABINE	4	1
DACTINOMYCIN	4	1
EPOETIN ALFA	4	1
FLOXURIDINE	4	1
GANCICLOVIR	4	1
HYDROXYUREA	4	1
IMETELSTAT SODIUM	4	1
MORPHINE SULFATE	4	1
OCTREOTIDE ACETATE	4	1
OFLOXACIN	4	1
PALONOSETRON HYDROCHLORIDE	4	1
PHENOBARBITAL	4	1
SARGRAMOSTIM	4	1
SUNITINIB MALATE	4	1
THIOTEPA	4	1
TRABECTEDIN	4	1
VANDETANIB	4	1
ALVOCIDIB	3	3
LAROMUSTINE	3	2